BIONEER

Investor Presentation

Disclaimer

This presentation has been prepared by Bioneer Corporation(the “Company”), with an aim to promote investors’ understanding of the Company.

The accuracy of the ‘forward-looking statements’ included in this presentation has not been independently verified. The forward-looking statements include projections and outlook of the Company concerning its business status and financial results, and include but are not limited to words, such as ‘expectation’, ‘forecast’, ‘plan’, ‘anticipation’ or ‘(E)’. The forward-looking statements are subject to changes in business environment and involve inherent risks and uncertainties.

Future expectations are based on current business environment and the Company’s management direction as of the date of presentation. Future projections may differ or change due to changes in business environment or due to strategic changes by the Company. The contents in this presentation may change without any prior notification. No part of the Company or any of its respective officers assume legal responsibility for any damages or losses that may have occurred from the use of this presentation, including errors and other mistakes that may be included in this presentation.

This presentation may not be reproduced in whole or in part, nor may any of its contents be divulged to any third party, unless prior consent by the Company has been granted.

Contents

Introduction

BIONEER Corporation

CEO	Han-Oh Park
Established on	Aug. 28th, 1992 (Listed on KOSDAQ : Dec. 29th, 2005)
No. of Employees	608 (as of 2022.09)
No. of R&D Employees	199 (as of 2022.09)

Shareholder Structure (as of 22.9.30)



BIONEER Family

BIONEER

- Life Sciences & MDx
  - Oligo DNA/RNA & Gene Synthesis
  - MDx Extraction Kits, Instruments
- Anti-Hair Loss Cosmeceutical
  - CosmeRNA
- Nano-Bio
  - Nano Beads
  - Carbon Nanotube (CNT)
  - Silver-coated Copper Nanowires

AceBiome

- Weight Management Probiotics
  - BNR17 Series
- Immune Probiotic
  - AB-Immune

siRNAgen THERAPEUTICS

- siRNA Therapeutics
  - SAMiRNA™

About Us

Cash-Cow Business Model



Corporate Governance



Business Divisions

I. Molecular Diagnostics

Molecular Diagnostics (MDx)

Market Prospect

Global Molecular Diagnostics Market



(Unit: USD Billion)

(Source: BIS. Molecular Diagnostics Market, 2021)

Growth Factors

Global Molecular Diagnostics Market is expected to reach **$24.2B** by 2031

Increasing demand and awareness on **POCT** (Point-of-Care Testing) diagnostic systems

Escalating elder population, outbreak of varied viral/respiratory diseases, and other diseases in need of treatment

Molecular Diagnostics (MDx)

Unmet Needs

MDx Plant Expansion

- Increased production capacity
- Development of 4th Generation MDx instruments



Internalized Manufacturing

- From raw materials to MDx instruments
- Cost-advantage & Production efficiency

MDx Ecosystem

- Superior level of sensitivity and specificity
- Customized MDx solution enables to target wider range of customers

Molecular Diagnostics (MDx)

CAPEX Expansion and Development of 4th Generation MDx System

BIONEER Global Center

$70M investment in Global Center to serve global market
4th Generation MDx instruments and nucleic acid extraction kits

* Production Line: ExiPrep™, AccuPrep®, Saliva, POCT(Exp.)

Partnered with FIND*

FIND
Diagnosis for all

POC MDx development project
- Financial and procedural support throughout R&D-validation-production-sales of IRON-qPCR/kits in LMICs

*FIND: Foundation for Innovative New Diagnostics (global non-profit organization for diagnostics)

4th Generation MDx System

POC: IRON-qPCR™
High-throughput: ExiStation™ FA 96/384

BIONEER

IRON-qPCR™

Symptom-based POC Multi-Analyte Test Platform

- **30-minute diagnostics with each syndromic cartridge**
- **Simultaneous testing up to 40 pathogens and its variants**

All in one system from 'Nucleic Acid Extraction Amplification'
Fully automatic from nucleic extraction to results analysis

Near patient Fast Diagnostics without a delay in sending samples to trained personnel or negative pressure chamber

Early detection of emerging infectious diseases via simultaneous diagnosis of pathogens causing same symptoms

Multiple Pipelines for Diagnosis On site △20 respiratory viruses △16 sexually transmitted infections △20 bacteria causing diarrhea

ExiStation™ FA 96/384

Fully-Automatic Molecular Diagnosis Platform Optimized for Large-scale Infectious Disease Testing

- **Tests 96 Samples within 96 minutes & tests anywhere**
- **Simultaneously detects up to 20 pathogens per test**

Full Scale Automation of 'Sample Tube De-capping Nucleic Acid Extraction Nucleic Acid Amplification' through "Load & Run" Function

Applying a fully automatic opening and closing system for the sample tube in the equipment, Protection of operator from the infection

Negative pressure chamber and sterilization units incorporated, with no biosafety workbench or negative pressure laboratory

Public facilities such as general hospitals, inspection centers and large ships, airports, ports, and concert halls

Molecular Diagnostics (MDx)

All-In-House production secured sensitivity, specificity, and cost-advantage

All-In-House Production

Raw Materials | Synthetic DNA/RNA | PCR Kits | MDx Instruments

Competitiveness in Quality · Cost-efficiency · Capacity

DNA/RNA/Gene Synthesis
- Ton-scale phosphonamidite capacity
- 100+ kinds of raw materials production
- Production capacity: 30,000+ oligonucleotides per day

MDx Kits AccuPower® PreMix Technology
- High Sensitivity based on Pyro-HotStart™ and Dual-HotStart™ technology

MDx Instruments
- Developed and commercialized MDx total solution

BIONEER MDx Ecosystem

MDx Kits | **MDx Instruments** (DNA/RNA Purification/Amplification)

Provides MDx Total Solution
- Nucleic Acid Extraction and PCR kits optimized to instrument
- Outstanding stability through patented lyophilized PreMix
- 40+ diagnostic kits portfolio, including SARS-CoV-2

*RT-PCR workflow = Nucleic Acid Extraction + Amplification

Nucleic Acid Extraction/Purification	PCR PreMix	Amplification
• Extract DNA/RNA from the sample	• Prepare mix to be amplified	• Nucleic Acid Amplification

II. Anti-Hair Loss Cosmeceutical

CosmeRNA Anti-Hair Loss Cosmeceutical

Androgenetic alopecia (AGA) Market Status

Current therapies bring significant QoL side effects

$3.5B

CAGR 6%
global alopecia market (2019)[1)]



58% sales from drug stores & retail pharmacies

North America accounts for ½ of global hair loss market with most of the sales coming from drugs stores and retail pharmacies[2)]



AGA affects up to **50% of males and females** worldwide and rising[1]

Current available therapies have severe side effects including erectile dysfunction, decreased libido, swelling, male breast cancer, dizziness, headache, rash and inconvenient dosage & administration

1. Data Bridge Market Research, 2020
2. Allied Market Research (AMR), 2021

CosmeRNA Anti-Hair Loss Cosmeceutical

Cosmeceutical + RNA = CosmeRNA

Product Launch Timeline (EU)



CosmeRNA Anti-Hair Loss Cosmeceutical

Androgenetic alopecia (AGA) caused by the over-stimulation of androgen receptor, the target of CosmeRNA



Dihydrotestosterone (DHT) binds to androgen receptor (AR) to induce hair cell apoptosis and hair loss

CosmeRNA inhibits androgen receptor (AR) to prevent hair loss

BIONEER

CosmeRNA Anti-Hair Loss Cosmeceutical

Research Published on scientific reports *

*online open access journal published by Nature Portfolio

OPEN

Weekly treatment with SAMiRNA targeting the androgen receptor ameliorates androgenetic alopecia

Sung-Il Yun[1,5], Sang-Kyu Lee[2,5], Eun-Ah Goh[2], Oh Seung Kwon[2], Woorim Choi[2], Jangseon Kim[2], Mi Sun Lee[2], Soon Ja Choi[2], Seung Sik Lim[1], Tae Kee Moon[3], Sin Hae Kim[3], Keeyeol Kyong[4], Gaewon Nam[4]✉ & Han-Oh Park[1,2]✉

Androgenetic alopecia (AGA) is the most common type of hair loss in men and women. Dihydrotestosterone (DHT) and androgen receptor (AR) levels are increased in patients with AGA, and DHT-AR signaling correlates strongly with AGA pathogenesis. In this study, treatment with self-assembled micelle inhibitory RNA (SAMiRNA) nanoparticle-type siRNA selectively suppressed AR expression in vitro. Clinical studies with application of SAMiRNA to the scalp and massaging to deliver it to the hair follicle confirmed its efficacy in AGA. For identification of a potent SAMiRNA for AR silencing, 547 SAMiRNA candidates were synthesized and screened. SAMiRNA-AR68 (AR68) was the most potent and could be efficiently delivered to human follicle dermal papilla cells (HFDPCs) and hair follicles, and this treatment decreased the AR mRNA and protein levels. We confirmed that 10 μM AR68 elicits no innate immune response in human PBMCs and no cytotoxicity up to 20 μM with HFDP and HaCaT cells. Clinical studies were performed in a randomized and double-blind manner with two different doses and frequencies. In the low-dose (0.5 mg/ml) clinical study, AR68 was applied three times per week for 24 weeks, and through quantitative analysis using a phototrichogram, we confirmed increases in total hair counts. In the 24-week long high-dose (5 mg/ml) clinical study, AR68 showed average additional hair growth of 1.3-1.9 hairs/cm² per month, which is comparable to finasteride. No side effects were observed. Therefore, SAMiRNA targeting AR mRNA is a potential novel topical treatment for AGA.

Androgenetic alopecia (AGA), commonly known as male pattern hair loss (MPHL) in men and female pattern hair loss (FPHL) in women, is the most common type of progressive hair loss[1–3]. Androgens, male hormones, are one of the causes of AGA[4]. Although the relationship between FPHL and androgen is unclear, FPHL is accompanied by hair follicle miniaturization and hair thinning, similar to MPHL[5]. The pathogenesis of both diseases is not yet completely understood, but its incidence has increased in recent years.

Androgen and AR signaling plays an essential role in regulating the hair cycle and skin pathogenesis, including in AGA[6–8]. Endogenous androgens include testosterone and dihydrotestosterone (DHT). DHT is a more potent androgen synthesized from testosterone by 5-α reductase and exhibits an – tenfold higher binding affinity with the androgen receptor (AR). DHT and AR levels are elevated in patients with AGA, and it has been reported that DHT-AR signaling is closely related to AGA pathogenesis[9–13]. Finasteride and dutasteride, which were developed as 5-α reductase inhibitors, have been approved by the FDA and are being used as the main treatments for AGA. However, these drugs have several side effects, such as a decrease in libido via decreases in DHT[14,15]. Hence, there is a need for a new treatment for AGA without such side effects. Since 5-α reductase is produced in various cells, including the male and female reproductive tracts, testes, and ovaries, inhibition of DHT synthesis by local treatment is not effective, and only systemic administration will result in effective treatment. Therefore, the best way to block DHT-AR signaling without inhibition of systematic DHT synthesis is suppression of AR expression in hair tissue alone. This method constitutes an appropriate strategy for AGA treatment with minimal side effects.

https://doi.org/10.1038/s41598-022-05544-w



Figure 5. Images of the change in hair loss following 24 consecutive weeks of applicati
0.5 mg/ml and placebo products. (**a**) Representative photographs of the forehead hairlir
groups at baseline and 8, 16 and 24 weeks after 0.5 mg/ml AR68 and placebo treatment
The phototrichogram analysis was performed at baseline and at 16 and 24 weeks. (**b**) Re
percentage of total hair count increments at 16 and 24 weeks compared to baseline.



Figure 6. Images of the change in hair loss following 24 consecutive weeks of application of SAMiRNA-AR68 at 5 mg/ml and placebo products. (**a**) Representative photographs of the forehead hairline and vertex of the two groups at baseline and 8, 16 and 24 weeks after 5 mg/ml AR68 and placebo treatment once a week. The phototrichogram analysis was performed at baseline and at 16 and 24 weeks. (**b**) Representative graph of the percentage of total hair count increments at 16 and 24 weeks compared to baseline.

BIONEER

Safety and Efficacy data of CosmeRNA

No drug-related AE in safety study (n=35) nor in the efficacy trial (n=60) were observed in the human clinical trials for cosmeceutical registration in Korea

Category	CosmeRNA (n=60)	Best in class (n=3177)
Active ingredient	SRN-011	finasteride
Classification	Cosmeceutical/OTC	Prescription
Formulation	**Topical**	**Oral**
Target	Androgen Receptor Inhibitor	5α-reductase Inhibitor
Usage Count	**Once a week**	**Once a day**
Efficacy (per 1 cm^2)	**Response rate**: 91% **Primary end point**: +1.9 hairs/mo (7.6 in 4 mo)	**Response rate**: 87.1% **Primary end point**: +1.6 hairs/mo (9.3 hairs in 6 mo)
Side Effect	**None**	**Erectile dysfunction, decreased libido, swelling, male breast cancer, dizziness, headache, skin rash**

Yun, SI., Lee, SK., Goh, EA. et al. Weekly treatment with SAMiRNA targeting the androgen receptor ameliorates androgenetic alopecia. Sci Rep 12, 1607 (2022). https://doi.org/10.1038/s41598-022-05544-w

CPNP Notification Plan

Notify CosmeRNA to CPNP by the end of 2022

Cosmetic Products Notification Portal (EU)

Selecting RP (Responsible Person)

Responsible for the product placed on the market, managing inspections of the supervisory authorities and inquiries

Formula Review & Product Test

Conduct product tests and prepare CPSR (Cosmetic Product Safety Report)

Product Labelling & Review

PIF (Product Information File)

PIF includes certificates/declarations, toxicological information, stability/efficacy test reports, CPSR, etc.

Notification on CPNP

Notify electronically to the European Commission

Post-market surveillance by RP

*Due to Brexit, UK is operating its independent platform SCPN(Submit a Cosmetic product Notification)

III. Probiotics

Probiotics

AceBiome
A Probiotic Company of BIONEER

Market Prospect



(Unit: USD Billion)
(Source: Data Bridge Market Research, 2022)

Growth Factors

Global market expected to reach **$114.1B** by 2029 with increasing interest in the wellness

AceBiome records **AAGR of 157%** (2019-21), aggressively expanding its market share

Highly scalable business from intestinal health, immune health, body fat reduction, and skincare

BIONEER

Probiotics

AceBiome
A Probiotic Company of BIONEER

Lactobacillus gasseri BNR17®, First MFDS approved probiotic strain in body fat reduction

Earnings: Probiotics Division ('18-'21)



Body fat reduction, proliferation of probiotics and healthy, regular bowel movement

600+ research papers related to *Lactobacillus gasseri* BNR17™ published in SCIE-level international journals

Awarded **"Ingredient of the Year in Weight Management"** at NutraIngredients-USA Awards 2018

Patented in **10** countries including US, China, Japan, Korea, Chile, and various European countries

Weight Management Probiotics
BNR Series

Immune Probiotics
AB-Immune

BIONEER

IV. siRNA Therapeutics

RNAi Therapeutics

Market Prospect



(Unit: USD Million)

(Source: Facts and Factors Market Report, 2021)

Growth Factors

Global RNAi Therapeutics market is expected to be worth **$2,493.7M** by 2026

RNAi Therapeutics is responsible for **40%** of annual pipeline growth

CAGR of 20.7%, which is one of the fastest growth rate in all therapeutics

RNAi Therapeutics

RNAi Challenges



SAMiRNA™ Platform

SAMiRNA™ (Self-Assembled-Micelle inhibitory RNA)

RNAi Challenges	SAMiRNA™	
Delivery beyond the liver	Extrahepatic delivery	Inflamed, adipogenic, neoplastic tissues in kidney, lung, skin, visceral fat, and brain via IV, ID, SC injection, and inhalation
Toxicity from innate immune stimulation	Demonstrated safety	Self-assembling single molecule design removes traditional toxicity problems of liposome-induced innate immune reaction
Challenging CMC & Manufacturing	Manufacturing ease	One-step automated solid-phase synthesis with no formulation or encapsulation step enable greener, easier manufacturing
Cold chain distribution	RT stability	Single molecule design prevents NP lysis at RT and humidity for 1-year, eliminating the need for cold chain distribution
International Protection	Strong IP portfolio	SAMiRNA™ platform is protected by 150+ patents approved and pending in major markets, (Platform FTO completed)

SAMiRNA™ (Self-Assembled-Micelle inhibitory RNA)

Combination of conjugation & NP encapsulation strategies
without any of their downsides for enhanced safety, bioavailability, stability, sustainability

Structure of SAMiRNA™ Platform



Conjugate



Nanoparticle

Varying the modular components can tune targetability & MoA for endosomal escape

*MoA : Mechanism of Action

Delivery is made more effective by excellent PK resulting from the nanoparticle structure

Strong IP positioning
(6 platform + 13 product patent families, 150+ total in key geography)

siRNA Challenges

siRNA challenges are conjugation and encapsulation, which come with significant downsides

Naked (Conjugated) RNAi	SAMiRNA™	Nanoparticle Encapsulation



Alnylam PHARMACEUTICALS · arrowhead pharmaceuticals · Dicerna pharmaceuticals · SILENCE THERAPEUTICS

Poor bioavailability & PK,
delivery limited to liver



Self-Assembled-Micelle Inhibitory RNA

Alnylam PHARMACEUTICALS · ARUNABIO · ReCode THERAPEUTICS

Toxicity, difficulty manufacturing
& scaling, unstable

SAMiRNA™ Pipelines



Financial Highlights

Q3 Earnings Summary

Revenue KRW 546B (QoQ +3.9%, YoY -14.7%)

Operating Income KRW 42B (QoQ +9,595.4%, YoY +4,154.1%)

[Consolidated | KRW Billion]	'22 Q3	'22 Q2	Q o Q	'21 Q3	Y o Y
Revenue	546	526	+3.9%	640	-14.7%
└ Bioneer Corp.	109	126	-12.9%	348	-68.5%
└ AceBiome	437	400	+9.1%	281	+55.2%
└ Others	-	-	-	5	-
Gross Income	417	405	+3.1%	510	-18.2%
Gross Margin (%)	*76.4%*	*77.0%*	*-0.6%p*	*79.7%*	*-3.3%p*
SG&A Expenses	375	404	-7.1%	509	-26.2%
Operating Income	42	0.4	+9,595.4%	0.9	+4,154.1%
Operating Margin (%)	*7.6%*	*0.08%*	*+7.52%p*	*0.2%*	*+7.4%p*
└ Bioneer Corp.	(57)	(61)	+7.2%	(43)	-34.1%
└ AceBiome	108	73	+48.1%	53	+103.2%
└ Others	(9)	(11)	+15.5%	(9)	+3.9%

Q3 Revenue Breakdown (Consolidated)

By Region



'22 Q3	[KRW Million]
Domestic	46,629
North America	2,418
Europe	686
Asia	4,471
Africa	200
Others	187
Total	**54,591**

By Product



'22 Q2	[KRW Million]
Oligo DNA/RNA	2,690
Diagnostic Kits	6,341
MDx Instruments	838
Others	1,095
Probiotics	43,627
Total	**54,591**

Financial Summary (Consolidated)

Financial Position [KRW Billion]

	'22 Q3	'21	'20
Assets	2,761	2,624	1,912
Current Assets	1,456	1,364	951
└ Cash & Cash Equivalents	265	494	327
Non-current Assets	1,338	1,260	961
└ Tangible Assets	1,202	1,135	830
Liabilities	530	548	432
Current Liabilities	427	508	351
Non-current Liabilities	103	40	81
Equity	2,263	2,076	1,480
Capital Stock	129	129	126
Capital Surplus	2,168	2,182	1,853
Retained Earnings	(104)	(281)	(523)

Net Cash & Financial Ratio [KRW Billion]



Cash Flow [KRW Billion]

	'22 Q3	'22 Q2	'21 Q3
Cash (Beginning of Period)	197	362	379
Cash Flow from Operating Activities	108	(35)	88
Cash Flow from Investing Activities	(74)	(128)	(37)
Cash Flow from Financing Activities	28	(2)	(54)
Cash (End of Period)	265	197	381

Income Statement (Consolidated)

[KRW Million]	2021					2022			QoQ	Y o Y
	Q1	Q2	Q3	Q4	SUM	Q1	Q2	Q3		
Revenue	49,882	54,109	63,986	55,767	223,744	61,454	52,561	54,591	+3.9%	-14.7%
ㄴ Bioneer Corp.	32,470	34,404	34,757	21,743	123,374	25,054	12,564	10,938	-12.9%	-68.5%
ㄴ AceBiome	17,382	20,810	28,119	34,024	100,335	36,395	39,997	43,653	+9.1%	+55.2%
ㄴ Others	30	-	5	-	35	5	-	-	-	-
Gross Income	37,515	42,860	51,016	42,806	174,197	47,924	40,459	41,724	+3.1%	-18.2%
Gross Margin (%)	*75.2%*	*79.2%*	*79.7%*	*76.8%*	*77.9%*	*78.0%*	*77.0%*	*76.4%*	*-0.6%p*	*-3.3%p*
SG&A Expenses	19,367	20,216	50,917	36,633	127,133	37,525	40,416	37,555	-7.1%	-26.2%
Operating Income	18,148	22,644	98	6,174	47,064	10,399	43	4,169	+9,595.4%	+4,154.1%
Operating Margin (%)	*36.4%*	*41.8%*	*0.2%*	*11.1%*	*21.0%*	*16.9%*	*0.08%*	*7.6%*	*+7.52%p*	*+7.4%p*
ㄴ Bioneer Corp.	16,596	15,159	(3,274)	2,027	30,508	6,869	(6,181)	(5,736)	+7.2%	-34.1%
ㄴ AceBiome	2,170	7,391	5,323	4,767	19,651	4,065	7,303	10,817	+48.1%	+103.2%
ㄴ Others	(618)	(908)	(949)	(620)	(3,095)	(535)	(1,079)	(912)	+15.5%	+3.9%
Non-Operating Income (Expenses)	2,128	554	(12,669)	6,201	(3,768)	1,256	1,716	2,318	+35.1%	*Turn to Profit*
Income Before Income Tax	20,276	23,198	(12,571)	12,375	43,278	11,655	1,791	6,487	+262.2%	*Turn to Profit*
Net Income	15,310	17,369	(9,277)	5,796	29,199	9,137	1,242	10,010	+706.0%	*Turn to Profit*
Net Margin (%)	*30.7%*	*32.1%*	*-14.5%*	*10.4%*	*13.1%*	*14.9%*	*2.36%*	*18.3%*	*+15.9%p*	*+32.8%p*

Appendix

Appendix : Molecular Diagnostics

MDx Total Solution Provider



Provided MDx System to 80+ countries worldwide

- Customized MDx solution for each client
- COVID-19 Pandemic : MDx Laboratory Service
- *All-In-House System* from raw materials to the end product enables stable production and supply

Appendix : Molecular Diagnostics

BIONEER MDx Total Solution

BIONEER MDx Ecosystem

16 Nucleic Acid Extraction Reagents

43 RT-PCR Reagents

3 Nucleic Acid Extraction Systems

2 Real-Time PCR Systems

System		ExiStation™			ExiStation™ 48	ExiPrep™ 96 Lite + Exicycler™ 96	ExiPrep™ 96 Lite + Exicycler™ 384
Nucleic Acid Extraction	System	*ExiPrep*™16Dx (Unit: 1)	ExiPrep™16Dx (Unit: 2)	ExiPrep™16Dx (Unit: 3)	ExiPrep™48Dx (Unit: 1)	ExiPrep™96 Lite (Unit: 1)	ExiPrep™96 Lite (Unit: 2)
	Reagent	ExiPrep™ Dx			ExiPrep™48	ExiPrep™96	Protonion™ 96
Real-Time PCR	System	*Exicycler*™ 96 (Unit: 1)	Exicycler™ 96 (Unit: 1)	Exicycler™ 96 (Unit: 1)	Exicycler™ 96 (Unit: 1)	Exicycler™ 96 (Unit: 1)	Exicycler™ 384 (Unit: 1)
	Reagent	AccuPower® series					
Tests/ 24hr		168 tests (12 run/1 day)	336 tests (12 run/1 day)	504 tests (12 run/1 day)	644 tests (14 run/1 day)	1,316 tests (8 run/1 day)	4,136 tests (11 run/1 day)

Appendix : Molecular Diagnostics

Product Portfolio: 40+ Diagnostic Kits

AccuPower® Kit Portfolio

COVID-19	• COVID-19 Kit	CE
	• SARS-CoV-2 Kit	CE
	• SARS-CoV-2 Multiples Kit	CE
Hepatitis & HIV	• HIV-1 Kit	CE 0197
	• HBV Kit	CE 0197
	• HCV Kit	CE 0197
Tuberculosis	• MTB Kit	CE
	• MTB & NTM Kit	CE
	• TB & MDR Kit	CE
	• TB & XDR Kit	CE
Sexually Transmitted Disease	• STI 8A Kit (CT, NG, UU, MG)	CE 0197
	• STI 8B Kit (TV, MH, HSV1, HSV2)	CE
	• STI 4C Kit (TP, UP, CA, GV)	CE
Respiratory Disease	• InfA Kit	CE
	• New InfA Kit	CE
	• CP Kit	
	• MP Kit	CE
	• MERS-CoV Kit	CE
Transplantation -related Disease	• CMV Kit	
	• EBV Kit	CE
	• BKV Kit	CE
Gastro-intestinal Disease	• Norovirus Kit	CE
	• Enterovirus Kit	CE
Human Papillomavirus	• HPV 16&18 Kit	CE
	• HPV Genotyping Kit	CE
	• hrHPV Kit	CE
Mosquito-borne Disease	• ZIKV multiplex Kit (ZIKV, DENV, CHIKV)	CE
Genotyping	• ApoE Kit	CE
	• Warfarin Kit	CE
	• HLA-B27 Kit	
	• TPMT Kit	CE
	• MTHFR Kit	CE
	• JAK2 V617F Kit	CE
	• Factor V Leiden Kit	CE

Appendix : Molecular Diagnostics

IRON-qPCR™

	BIONEER IRON-qPCR™	**Competitor S**	**Competitor C**
			
Size (cm)	30(W) X 29(D) X 40(H)	Console: 17(W) X 23(D) X 39(H) Module: 14(W) X 33(D) X 32(H)	16.1(W) X 29.7(D) X 30.4(H)
Sample Capacity	2	1	2
Targets up to	40	12	10
Time to first results	30 min	60 min	60 min

Appendix : Molecular Diagnostics

ExiStation™ FA 96/384

	BIONEER ExiStation™ FA 96/384	**Competitor R**	**Competitor H**	**Competitor A**
				
Size (cm)	165(W) x 75(D) x 85(H)	292(W) x 216(D) x 129(H)	192(W) x 81.5(D) x175(H)	249(W) x 102(D) x 188(H)
Weight (kg)	320	1,624	363	1,021
Targets up to	20개	5개	5개	5개
Maximum throughput (8hr)	864	384	275	300
Time to first results	90 min	≤ 180 min	≤ 210 min	≤ 115 min

BIONEER

IR Contact

irteam@bioneer.co.kr

+82 2 739 6083